Synapse Open Synapse
Biology

Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data

GEN · · 6 min read

Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%.

Latest from GEN